Pseudoendocrine sarcoma: clinicopathologic, molecular, and epigenetic features of one case

Virchows Arch. 2023 Dec;483(6):899-904. doi: 10.1007/s00428-023-03695-3. Epub 2023 Nov 13.

Abstract

Pseudoendocrine sarcoma (PES) is a recently described neoplasm typically arising in paravertebral soft tissues. Histologically, PES resembles well-differentiated neuroendocrine tumors but lacks expression of epithelial/neuroendocrine markers, and most show aberrant nuclear β-catenin positivity. We describe the clinicopathological and molecular features and DNA methylation profile of one PES. A resected paraspinal soft tissue mass in a 52-year-old man showed a neuroendocrine-like neoplasm, negative for keratin, and synaptophysin and showing diffuse nuclear β-catenin expression. Targeted NGS confirmed a CTNNB1 (p.S37C) mutation. Whole genome methylation analysis showed no match to any methylation class in the central nervous system tumor (versions 11b6 and 12b6) or sarcoma classifier (calibrated scores of ≤0.3), but clustered together with a recently reported PES in which methylation analysis was also performed. He remained disease-free for 18 months after surgery, followed by chemoradiation. As more cases are examined, our findings suggest that PES may have a unique methylation profiling signature.

Keywords: CTTNB1 mutations; Neuroendocrine-like; Pseudoendocrine sarcoma; Soft tissue; Whole-genome methylation profiling.

Publication types

  • Case Reports

MeSH terms

  • Biomarkers, Tumor / genetics
  • Epigenesis, Genetic / genetics
  • Humans
  • Male
  • Middle Aged
  • Mutation
  • Sarcoma* / diagnosis
  • Sarcoma* / genetics
  • Sarcoma* / pathology
  • Soft Tissue Neoplasms* / genetics
  • beta Catenin / genetics

Substances

  • beta Catenin
  • Biomarkers, Tumor

Grants and funding